GlassScriptPhysician profile
Christopher B Skvarka
NPI 1306014550
$8,723.75
in general payments reported to CMS, 2019-2025
30 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $518 · 2021: $776 · 2022: $1,064 · 2023: $1,620 · 2024: $1,960 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,836 · Education: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,836.25 |
| Education | $533.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,085.66 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,305.88 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $955.79 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $614.08 | 2019-2025 | |
| Genzyme Corporation | $574.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $510.69 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $423.78 | 2020-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $329.38 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $282.09 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $254.77 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $197.29 | 2023-2025 | Zoryve |
| Biofrontera INC. | $166.37 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $141.50 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $117.55 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $103.55 | 2023 | Puraply |
| Celgene Corporation | $90.00 | 2019 | |
| Kerecis Limited | $78.30 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Vyne Pharmaceuticals INC. | $67.69 | 2020-2021 | |
| Dermavant Sciences, INC. | $63.17 | 2023-2024 | Vtama |
| Ucb, INC. | $47.47 | 2023-2024 | Bimzelx, Cimzia |
| Helsinn Therapeutics (U.S.), INC. | $36.96 | 2019-2022 | |
| Journey Medical Corporation | $26.62 | 2022 | |
| Botanix Sb INC | $25.25 | 2025 | Sofdra |
| Genentech USA, INC. | $24.55 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.18 | 2021 | |
| Galderma Laboratories, L.P. | $19.45 | 2024 | |
| Myriad Genetic Laboratories, INC. | $11.85 | 2021 | |
| Misonix INC | $11.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Skvarka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.